The history of Viagra and its creator , copyright, presents a fascinating picture for prospective investors. While the iconic drug initially fueled enormous earnings, its patent has ended, leading to competing alternatives flooding the market . This decline in value presents a real hurdle for copyright and any fund considering a heavy holding in th